Heather Wilson, APRN
Primary Care · West Hartford, CTNPI 1497264709
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $478, more than ten times the $29 reported in 2023.
Across 41 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$111
- Xeris Pharmaceuticals, Inc.$94
- AbbVie$89
- Amgen$86
- Boehringer Ingelheim$84
- Bayer$67
- plus $335 from 12 others
What the payments were for
- Food & beverage$865100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $111 |
| Xeris Pharmaceuticals, Inc. | 5 | $94 |
| AbbVie | 3 | $89 |
| Amgen | 4 | $86 |
| Boehringer Ingelheim | 3 | $84 |
| Bayer | 4 | $67 |
| Antares Pharma, Inc. | 2 | $54 |
| Sequel Med Tech, LLC | 3 | $52 |
| Lilly USA, LLC | 2 | $41 |
| Radius Health, Inc. | 1 | $33 |
| Tolmar, Inc. | 2 | $31 |
| Medtronic | 1 | $29 |
| Sandoz | 1 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
| RGH Enterprises LLC | 1 | $16 |
| BETA Bionics, Inc. | 1 | $16 |
| Cequr Corporation | 1 | $2 |
How this compares
$865 in reported general payments places this provider in the 75th percentile of 111 primary care providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 34 | $49,802 |
| MounjaroTirzepatide | 13 | $21,826 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $7,288 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,879 |
| Olmesartan Medoxomil | 166 | $5,528 |
| Rosuvastatin Calcium | 158 | $4,879 |
| Atorvastatin Calcium | 236 | $3,575 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 89 | $2,708 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $2,540 |
| Ezetimibe | 39 | $2,020 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 12 | $1,839 |
| Metoprolol Succinate | 83 | $1,786 |
| Levothyroxine Sodium | 141 | $1,570 |
| PaxlovidNirmatrelvir/Ritonavir | 19 | $1,429 |
| Tamsulosin Hcl | 58 | $1,429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $41 | $21,82613 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $1,570141 claims |
| AbbVieSynthroid | $89 | $1,25915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 111 primary care providers in Connecticut.
Other primary care in West Hartford
- Gladys QuinonesWest Hartford$2K
- Lisa KnollWest Hartford$2K
- Margaret BrighamWest Hartford$1K
- Anita ObidigboWest Hartford$311
- Kelly NolinEnfield$16K
- Deanna BallardDanbury$7K
- Jacqueline VelezBridgeport$7K
- Joyce WallHamden$5K
- Catherine KrenickyPawcatuck$5K
- Christopher AndersonGroton$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.